Morphine modulates NFκB activation in macrophages

被引:145
作者
Roy, S
Cain, KJ
Chapin, RB
Charboneau, RG
Barke, RA
机构
[1] Vet Adm Med Ctr, Dept Pharmacol, Minneapolis, MN 55417 USA
[2] Vet Adm Med Ctr, Dept Surg, Minneapolis, MN 55417 USA
[3] Univ Minnesota, Minneapolis, MN 55417 USA
关键词
D O I
10.1006/bbrc.1998.8415
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chronic use of morphine affects the immune system and predisposes an individual to opportunistic infections. Macrophages play an important role in conferring a first line of defense against invading pathogens. Understanding the mechanisms by Which morphine affects the functioning of macrophages would have significant therapeutic benefit in treatment against infections such as HIV and AIDS related syndromes. Two of the major cytokines secreted by activated macrophages are Interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha). Our studies show that morphine differentially modulates lipopolysaccharide (LPS) induced expression of IL-6 and TNF-alpha. Nanomolar concentrations of morphine synergize with LPS and augment the secretion of both IL-6 and TNF-alpha. However, at micromolar concentrations morphine inhibits LPS induced synthesis of IL-6 and TNF-alpha. Expression of both these cytokine genes is dependent on the activation of a transcription factor, NF kappa B. Interestingly, morphine treatment also modulated the activation of NF kappa B by LPS, Pretreatment with a low dose of morphine (nanomolar) resulted in an increase in NF kappa B activation. In contrast pretreatment with a high dose of morphine (micromolar) led to a significant decrease in NF kappa B activation. Furthermore unlike the augmentation which was naloxone reversible, the inhibition of NF kappa B by morphine was not reversed by naloxone, suggesting the involvement of a nonclassical opioid receptor. (C) 1998 Academic Press.
引用
收藏
页码:392 / 396
页数:5
相关论文
共 27 条
[1]   Inhibition of primary murine macrophage cytokine production in vitro following treatment with the kappa-opioid agonist U50,488H [J].
Alicea, C ;
Belkowski, S ;
Eisenstein, TK ;
Adler, MW ;
Rogers, TJ .
JOURNAL OF NEUROIMMUNOLOGY, 1996, 64 (01) :83-90
[2]  
Ausubel F. M., 1989, CURRENT PROTOCOLS MO, V1
[3]  
AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, V2
[4]  
BAUERLE PA, 1988, CELL, V53, P211
[5]  
BIAN TH, 1995, ACTA PHARM SINIC, V16, P449
[6]  
BURKE RA, 1994, SURGERY, V116, P141
[7]  
BUSSIERE JL, 1993, J PHARMACOL EXP THER, V264, P591
[8]   REGULATION OF TUMOR NECROSIS FACTOR-ALPHA TRANSCRIPTION IN MACROPHAGES - INVOLVEMENT OF 4 KAPPA-B-LIKE MOTIFS AND OF CONSTITUTIVE AND INDUCIBLE FORMS OF NF-KAPPA-B [J].
COLLART, MA ;
BAEUERLE, P ;
VASSALLI, P .
MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (04) :1498-1506
[9]  
FECHO K, 1994, J IMMUNOL, V152, P5845
[10]   Involvement of CCAAT/enhancer-binding protein and nuclear factor-kappa B binding sites in interleukin-6 promoter inhibition by estrogens [J].
Galien, R ;
Evans, HF ;
Garcia, T .
MOLECULAR ENDOCRINOLOGY, 1996, 10 (06) :713-722